Kailera Therapeutics, Inc.
About Kailera Therapeutics, Inc.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$78.9M
- Total assets
- $624.8M
- Market cap
- $2.5B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.5B
- Shares outstanding
- 127.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 17, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $78.9M.
- Trading 24% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Kailera Therapeutics, Inc..
Write a review
News about Kailera Therapeutics, Inc.
News & sentiment via Polygon.io
